Alvotech

Alvotech announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for subcutaneous administration via prefilled syringe and autoinjector. This acceptance follows the May acceptance of Alvotech's BLA for AVT16, the intravenous presentation, meaning the company's vedolizumab biosimilar program now covers both intravenous and subcutaneous forms. Under a partnership with Teva Pharmaceutical Industries, Alvotech handles development and manufacturing while Teva manages commercialization. The BLA is supported by analytical, pharmacokinetic, and immunogenicity data, and a pivotal pharmacokinetic study met all primary endpoints in February 2026. If approved, AVT80 would expand biosimilar options for patients with ulcerative colitis and Crohn's disease in the United States.

Alvotech's stock climbed 11.7% after the company announced an expanded licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues. This deal, announced in August 2026, broadens Alvotech's access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply. The expansion could modestly support near-term milestones, but the key short-term catalyst remains timely FDA and EMA decisions on late-stage assets. Alvotech's 2026 revenue guidance of US$650 million to US$700 million already relies heavily on product and milestone flows, so any payments from Lotus would sit inside that ambitious framework. The company's recent swing back to a net loss in the first half of 2026 underscores its dependence on approval timing and partner ramp-up.

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two biosimilar candidates in the United States and selected Asian markets. The deal covers AVT34, a proposed biosimilar to Imfinzi, and AVT87, a proposed biosimilar to Hemlibra. Under a semi-exclusive U.S. agreement, Alvotech retains the right to commercialize both products directly alongside Lotus, while Lotus will commercialize through its U.S. subsidiary Alvogen. In Asia, Lotus gets exclusive rights in eight markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. The agreement has a potential value to Alvotech of up to approximately $150 million in upfront and milestone payments, plus ongoing supply revenues.

Alvotech reported first-half 2026 revenue of $212 million, down from $306 million a year earlier, as manufacturing slowed during facility and quality-system improvements at its Reykjavik site. Adjusted EBITDA was $47 million for the first six months, compared with $54 million in the prior-year period, while gross margin was 54%, versus 55% a year earlier. Management said production returned to planned levels near the end of the second quarter and reaffirmed full-year guidance of $650 million to $700 million in revenue and $180 million to $220 million in adjusted EBITDA. The company strengthened liquidity through a $165 million equity offering and a term loan facility of up to $75 million, providing approximately $240 million in new capital for manufacturing, pipeline investment and commercialization. The FDA closed its Reykjavik inspection with a Voluntary Action Indicated classification, and reviews are underway for biosimilar applications targeting Simponi Aria, EYLEA and Prolia/Xgeva, with potential U.S. approvals expected in the fourth quarter of 2026.

Several biotech stocks posted sharp gains on Wednesday, led by SciSparc after its subsidiary completed internal validation of a quantum sampling platform for clinical trial data. SciSparc closed at $9.09, up 70.54%, following the announcement that NeuroThera Labs successfully validated the platform being advanced by CliniQuantum, in which NeuroThera holds a 54.01% ownership interest. Avantor rose 15.78% to $14.38 after reporting second-quarter net sales of $1.69 billion and raising its full-year adjusted EPS guidance to $0.80 to $0.83 from $0.77 to $0.83. NeoGenomics gained 13.96% to $15.27 after second-quarter consolidated revenue increased 11% to $202 million and the company lifted its full-year revenue outlook to $802 million to $806 million from $797 million to $803 million. Alvotech climbed 13.87% to $3.53 after the FDA classified the inspection of its Reykjavik manufacturing facility as Voluntary Action Indicated, a step forward for its biosimilar applications. Sanara MedTech surged 13.55% to $30.25 after agreeing to be acquired by MiMedx Group in a cash-and-stock deal valued at $35 per share, or about $350 million in total enterprise value. LB Pharmaceuticals advanced 11.62% to $39.00 after securing a $150 million private placement and accelerating the timeline for topline results from its Phase 3 schizophrenia trial to the first half of 2027.

Alvotech announced that the U.S. FDA has successfully closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA classified the site as Voluntary Action Indicated, signaling that any observations identified during the inspection have been adequately addressed. CEO Lisa Graver said the closure reflects the company's ongoing commitment to strengthening its quality systems and manufacturing operations, adding that Alvotech continues to work with the FDA to advance recent Biologics License Applications toward approval. The company recently resubmitted BLAs for AVT05, a biosimilar to Simponi, and AVT06, a biosimilar to Eylea, and the FDA accepted the submission of AVT16, a proposed biosimilar to Entyvio, in June 2026. Alvotech has five biosimilars already approved and marketed globally, with a pipeline of 13 disclosed candidates. The stock is currently trading at $3.53, up 13.87 percent.

Alvotech stock may be undervalued following its $125 million public offering, with the company screening as attractively priced on several valuation measures. The share price has declined about 64% over the past five years, yet the stock trades at a price-to-sales ratio of 2.2 times, well below the biotech industry average of 12.0 times and the peer average of 6.5 times. A fair P/S ratio implied by Simply Wall St's model sits at about 5.1 times, more than double the current level, suggesting investors are paying a lower price for Alvotech's sales than might be expected. The company's biosimilar pipeline progress, including the FDA review of AVT16, and the recent capital raise support the investment case, though increased leverage and ongoing funding needs may keep the perceived risk profile elevated. The key question is whether Alvotech can convert its pipeline and capital raises into durable revenue and margin gains that prompt a rerating, or whether the current valuation discount proves to be a value trap.

Alvotech has amended its credit agreement to add a new US$75 million term loan facility led by GoldenTree Asset Management, following a US$165 million equity raise in June 2026, giving the company access to US$240 million in additional capital. The funds will support its biosimilar pipeline, product launches, and global expansion. The equity raise included Celtic Lux increasing its stake to about 27.5%. The new term loan carries a 12.5% interest rate, which keeps leverage risk on the radar. The financing reshapes Alvotech's balance sheet and could influence how investors view its ability to execute growth plans.

Celtic Lux Holdings S.a. r.l., formerly known as Alvogen Lux Holdings S.a. r.l., acquired 10,133,333 shares in Alvotech at a price of USD 3.75 per share. The transaction, disclosed in a filing with the Luxembourg Commission de Surveillance du Secteur Financier, took place on June 16, 2026.